Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
Abstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-it...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-08-01
|
| Series: | npj Schizophrenia |
| Online Access: | https://doi.org/10.1038/s41537-021-00168-x |
| _version_ | 1797643062180052992 |
|---|---|
| author | Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard |
| author_facet | Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard |
| author_sort | Fredrik Hieronymus |
| collection | DOAJ |
| description | Abstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group. |
| first_indexed | 2024-03-11T14:09:13Z |
| format | Article |
| id | doaj.art-6e2551eb683541798116ff0d4547bbfa |
| institution | Directory Open Access Journal |
| issn | 2334-265X |
| language | English |
| last_indexed | 2024-03-11T14:09:13Z |
| publishDate | 2021-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Schizophrenia |
| spelling | doaj.art-6e2551eb683541798116ff0d4547bbfa2023-11-02T00:41:45ZengNature Portfolionpj Schizophrenia2334-265X2021-08-017111010.1038/s41537-021-00168-xAntipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysisFredrik Hieronymus0Pernille Kølbæk1Christoph U. Correll2Søren D. Østergaard3Department of Clinical Medicine, Aarhus UniversityDepartment of Clinical Medicine, Aarhus UniversityDivision of Psychiatry Research, The Zucker Hillside HospitalDepartment of Clinical Medicine, Aarhus UniversityAbstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group.https://doi.org/10.1038/s41537-021-00168-x |
| spellingShingle | Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis npj Schizophrenia |
| title | Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis |
| title_full | Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis |
| title_fullStr | Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis |
| title_full_unstemmed | Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis |
| title_short | Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis |
| title_sort | antipsychotic placebo separation on the panss 6 subscale as compared to the panss 30 a pooled participant level analysis |
| url | https://doi.org/10.1038/s41537-021-00168-x |
| work_keys_str_mv | AT fredrikhieronymus antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT pernillekølbæk antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT christophucorrell antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT sørendøstergaard antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis |